Search clinical trials for: CARBOPLATIN

Total 3137 results

Qilu Pharmaceutical Co., Ltd.

Recruiting

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

METASTATIC CERVICAL CANCER

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） (neoSCORE Ⅱ)

Squamous Cell Non-small Cell Lung Cancer

China
Caigang Liu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Adjuvant Treatment of Breast Cancer

Breast Cancer

China
University of Chicago

Recruiting

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head Cancer | Throat Carcinoma

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

China
Ohio State University Comprehensive Cancer Center

Recruiting

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Endometrioid... and other conditions

United States
D3 Bio (Wuxi) Co., Ltd

Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

KRAS P.G12C

Australia, Korea, Republic of, China, United States, Hong Kong
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
Taofeek Owonikoko
AstraZeneca

Recruiting

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Extensive-stage Small-cell Lung Cancer

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer (Elechtra)

Vulvar Cancer

Italy
Jiangsu Cancer Institute & Hospital

Recruiting

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (LATE)

Chemoradiation | Esophageal Squamous Cell Carcinoma | Tislelizumab

China
Heath Skinner

Recruiting

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Oropharynx Cancer

United States
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Not yet recruiting

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

GEP-NET

Taiwan
Fundación GECP

Recruiting

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS)

Small Cell Lung Cancer Extensive Stage

Spain
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
BeiGene

Recruiting

Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Solid Tumor, Adult

United States, Australia, New Zealand, China, Korea, Republic of
Henan Cancer Hospital

Recruiting

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Fudan University

Recruiting

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Ovarian Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial (N6C)

Cervical Cancer | Neoadjuvant Chemotherapy | Bulky Neoplasm

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Amgen

Recruiting

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Taiwan, Switzerland, Spain, Canada, Israel, Germany, France, Belgium, Australia, Japan, Italy, Denmark
Rutgers, The State University of New Jersey

Recruiting

ATATcH Alternating Treatment Plans for Advanced Cancer

Head and Neck Cancer | Lung Cancer

United States
Shanghai Henlius Biotech

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Small-cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

United States, China, Greece, Spain, Austria, Czechia, Germany, Hungary, Latvia, Netherlands, Poland
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Sun Yat-sen University
GeneCast Biotechnology Co., Ltd.; Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA (FOCUS-C)

Non-small Cell Lung Cancer

China
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors

Korea, Republic of, United States, Australia, Taiwan, Poland, Canada, Hong Kong, United Kingdom
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Ovarian Cancer
People's Hospital of Quzhou

Recruiting

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Recruiting

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Bladder Cancer | Small Cell Neuroendocrine Carcinoma of Bladder | Urothelial Carcinoma Bladder

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
Amsterdam UMC, location VUmc

Recruiting

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)

Non-Small Cell Lung Cancer

Netherlands
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Brazil, Chile, China, Costa Rica, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Spain, Turkey, Portugal, Romania, South Africa
Yonsei University

Not yet recruiting

Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients (NEOS)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Gustave Roussy, Cancer Campus, Grand Paris; Institut Curie; CarThera

Recruiting

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients (SONOKID)

Malignant Glioma | Embryonal Tumor | Malignant Brain Tumor

France
University of Malaya
Merck Sharp & Dohme LLC; Cancer Research Malaysia; National Cancer Institute,... and other collaborators

Recruiting

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) (PIPER)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Malaysia
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Goethe University

Recruiting

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IV | NSCLC Stage IIIB

Germany
Beijing Sanbo Brain Hospital

Recruiting

Modified CV Regimen in Optic Pathway Glioma

Optic Glioma | Pediatric Brain Tumor, Optic Nerve Glioma

China
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Unity Health Toronto
National Institutes of Health (NIH)

Recruiting

Sirolimus for Nosebleeds in HHT

Epistaxis | Hereditary Hemorrhagic Telangiectasia | Nosebleeds

Canada
Qingdao Central Hospital

Recruiting

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

PFS | OS

China

Search clinical trials for: CARBOPLATIN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations